Latest News -Mito Advocacy
UMDF, LHON Collective Issue Statement on the FDA’s Decision Not to Approve Idebenone
UMDF is disappointed by the U.S. Food and Drug Administration’s (FDA) decision not to approve idebenone for Leber Hereditary Optic Neuropathy...
Read moreREAD THE LETTER: Leading Clinicians and Researchers Urge FDA to Reconsider Path Forward for DCA in Pyruvate Dehydrogenase Complex Deficiency
Click the Expand Button in the bottom right on the widget for a larger, full-screen view of the...
Read moreUMDF Joins Other Mito Advocacy Groups to Issue Statement and Call to Action Regarding the FDA’s DCA Denial
Sept. 4, 2025 — Earlier today, Saol Therapeutics shared the U.S. Food and Drug Administration (FDA) has issued a Complete Response...
Read moreAdvocacy Action: Ask FDA to Reconsider Elamipretide Decision
Barth Syndrome Foundation, UMDF, and MitoAction leadership were recently notified by Stealth BioTherapeutics that FDA has refused their request...
Read more